Depression And COVID-19 Vaccines: US FDA Notes ‘Imbalance’ In Novavax Trial For Adolescents
But agency assessors also said there did not appear to be a biological reason for the vaccine to cause depression when granting the emergency use authorization for use of the Novavax vaccine in 12- to 17-year-olds.
You may also be interested in...
CDC advisory panel members voice concerns about mix-ups in the administration of COVID-19 vaccines. Pfizer’s bivalent and monovalent vaccines have the same gray cap while Moderna has different colored caps for its two versions.
FDA Commissioner says the new shots will skip advisory committee review after June meeting on reformulation. ‘As we know from prior experience, strain changes can be made without affecting safety.’
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.